Kornimate/medical-research-clean huggingface dataset:
asthma with nasal polyposis

Conditions: Asthma; Nasal Polyps

Summary: asthma is often associated with various comorbidities that may influence its clinical expression. among those, chronic rhinosinusitis with nasal polyposis (crswnp) is observed in 5% of cases. asthmatic patients with crswnp appear to have more severe and poorly controlled asthma, as well as greater bronchial and systemic inflammation, especially those using inhaled corticosteroids as control medication. however, this remains to be validated. in the last decade, there has been interest labeled for phenotyping of asthma and crswnp. however, there is scarce data on the phenotype of asthma with crswnp. this study aims to describe the phenotype of asthmatic patients with crswnp according to the clinical, physiological and inflammatory characteristics and whether there is a more severe phenotype related to the dose of inhaled corticosteroids and the percentage of induced sputum eosinophils.

this study will compare the characteristics of asthmatic patients with crswnp with those without crswnp.

Eligibility criteria:
inclusion criteria: * 1. aged 18 years and over 2. with a proven diagnosis of asthma as defined by one of the above criteria of current guidelines: 1. forced expiratory volume in one second (fev1) increase by at least 12% (and ≥200 ml) after administration of a bronchodilator 2. current asthma symptoms and a methacholine provocative concentration inducing a 20% fall in fev1 (pc20) \<16 mg/ml 3. a respirologist's current diagnosis of asthma found in the patient's medical report 3. non-smokers or smokers/ex-smokers defined as someone with a smoking history \<10 pack-years 4. stable asthma and asthma medication for at least 4 weeks before data analysis 5. written informed consent obtained for inclusion in the database patients with crswnp 1. with a proven diagnosis of crswnp, based on endoscopy and defined as the presence of endoscopically visible bilateral polyps growing from the middle meatus with or without involvement of the nasal cavities exclusion criteria: 1. any respiratory disease apart from asthma and crswnp 2. current or ex-smokers should not have a smoking history ≥10 pack-years before data analysis. patients who administer nicotine in other forms (patches, chew tobacco, e-cigarette, etc.) will be excluded 3. unstable asthma medication \<4 weeks before index date 4. asthma exacerbation (see definition below) \<4 weeks before index date 5. respiratory tract infection \<4 weeks before index date

Keywords: asthma chronic rhinosinusitis nasal polyposis
mineralocorticoid receptor in the treatment of severe depression

Conditions: Major Depression

Summary: the proposed research aims to compare the onset of action and the efficacy of fludrocortisone, a mineralocorticoid receptor agonist vs. spironolactone, a mineralocorticoid antagonist, vs. placebo as augmentation to a selective serotonin reuptake inhibitor (ssri) in 65 inpatients with severe depression. the study will also explore the utility of the hypothalamic-pituitary-adrenal (hpa) axis in predicting treatment response. the study will be a 5-week randomized and double-blind trial of fludrocortisone vs. spironolactone vs. placebo during three years.


Eligibility criteria:
inclusion criteria: * depressed male and female inpatients according to dsm-iv * age between 18 and 70 years * minimum of 17-items hamilton depression score of 18 * informed consent signed exclusion criteria: * relevant medical or neurological disorders * pregnancy or unsure contraception * relevant psychiatric comorbidity * active alcohol or other substance abuse/dependance * contraindications to ssri, fludrocortisone, or spironolactone * steroid medication
panc ca risk model & biomarker testing in high-risk cohort

Conditions: Pancreatic Adenocarcinoma

Summary: the purpose of this study is to test a double screening strategy for pancreatic cancer, based on a model developed using patient medical records. investigators would also like to test whether adding specific blood tests, can further help identify people who have a higher risk of pancreatic cancer than the general population, and would benefit from imaging in order to detect cancer early.

this research aims to identify people who have a higher risk of pancreatic cancer than the general population, by testing a double-screening strategy for pancreatic cancer. the purpose is to allow early detection of cancer, which potentially leads to cure. the double-screening will include a computer-based model developed using clinical data from medical records, and three different blood tests for early detection of pancreatic cancer. participation in this study involves having medical records followed up for up to three years, and a single donation of blood specimens. - this is a combined retrospective and prospective review: * the first part of the study, involves collection of retrospective data from electronic health record database (for the 3 collaborating hcos) in order to deploy our ehr model, so that a high-risk group for pancreatic cancer can be identified. all individuals stratified into low, intermediate or high risk groups by the model, will be prospectively, electronically followed to assess outcome. * the second stage is prospective, and involves requesting biological specimen donations from participants identified as high-risk, for biomarker testing. the prospective "observation period" is up to 3 years (depending on each subject's index date at retrospective recruitment and outcome). biological specimens will be collected during the prospective "observation period,"

Eligibility criteria:
inclusion criteria: * study population for part 1 of study: -- inclusion criteria: i) male and females age \>= 50 years; ii) at least one clinical visit to an outpatient clinic of the hco, within the last year, before the study start date. * study population for part 2 of study: * i) model-assigned high-risk subjects; ii) male and females age \>= 50 years; iii) at least one clinical visit to an outpatient clinic of the hco, within the last year, before the study start date exclusion criteria: * exclusion criteria for part 1 of study: * personal history of pdac or current pdac * age below 50. * exclusion criteria for part 2 of study * model-assigned low or intermediate risk subjects * personal history of pdac or current pdac * age below 50.

Keywords: pancreatic adenocarcinoma
polycythemia vera, myelofibrosis and essential thrombocythemia: identification of pv, mf & et genes

Conditions: Polycythemia Vera; Essential Thrombocythemia; Myelofibrosis

Summary: the purpose of this project is to find genes whose mutations cause polycythemia vera, essential thrombocythemia and primary myelofibrosis.

polycythemia vera (pv), essential thrombocythemia (et) and primary myelofibrosis (pmf), also known as the philadelphia chromosome negative myeloproliferative disorders (mpds), are not congenital, but acquired. the purpose of this project is to find genes whose mutations cause these disorders, as well as improve diagnostic measures for these diseases. when this is accomplished new therapies to control and eventually cure the disease can be designed. all subjects will be asked to donate 4-6 teaspoons of blood. on occasion, if the blood cells from a particular sample do not grow well and the dna from that sample is used up or other tests are needed, we may ask to collect additional samples. in patients who have undergone a bone marrow biopsy as part of their clinical evaluation, we will test the reproducibility between pathologists for the revised 2008 who diagnostic criteria to diagnose myeloproliferative disorders (mpd).

Eligibility criteria:
inclusion criteria: 1. patients with an elevated hemoglobin concentration (\>18 in males and \>16 in females) and who are suspected to have congenital or acquired primary polycythemia 2. patients with a persistent thrombocytosis (\>400,000) that does not have an obvious secondary cause 3. patients with a bone marrow biopsy that shows increased cellularity and fibrosis 4. patients where there is clinical concern for primary myelofibrosis, such as anemia in combination with leukocytosis, thrombocytosis, splenomegaly and/or a leukoerythroblastic blood smear 5. patients with thrombosis at unusual sites, such as budd-chiari syndrome, can have early pv before hemoglobin is elevated, these patients will also be included. exclusion criteria: 1. subjects who have a known acquired cause of polycythemia (increased hemoglobin/hematocrit) such as people living in high altitudes (in excess of 14,000 feet), subjects with heart disease, left to right heart shunt, severe hypoxia or severe pulmonary disease will be excluded from this study. 2. subjects with a known acquired cause of thrombocytosis. 3. subjects will be excluded if they cannot demonstrate decision making capacity sufficient to agree or decline the blood drawing or use of their blood for the study.

Keywords: myeloproliferative disorders hematological malignancies polycythemia vera essential thrombocythemia myelofibrosis genetics chronic leukemia
minimal risk registry of endoscopic image and pathology correlation for fujiflim

Conditions: Gastro-Intestinal Disorder

Summary: the purpose of this study is to see if advanced endoscopic imaging may be helpful to accurately distinguish pathological tissue from normal tissue and guide therapy of endoscopically identified pathology.

in this registry, the fujifilm 4-led system, which is considered non significant risk, will be used for routine endoscopic procedures at mayo clinic florida and rochester. where indicated and based on clinical standards of care, a biopsy or tissue removal will be performed. immediately prior to tissue removal, a standard set of electronic images will be captured including white light, bli, bli-bright, lci. each image will be stored in high resolution lossless format and later correlated with the final clinical and histological diagnosis.

Eligibility criteria:
inclusion criteria: 1. all patients age 18-100 undergoing planned upper or lower endoscopy at mayo clinic rochester 2. informed consent exclusion criteria: 1. patient unwilling to provide informed consent

Keywords: endoscopic image fujifilm blue light imaging
healthy eating for my infant (hemi)

Conditions: Pediatric Obesity

Summary: infants from underserved and minority backgrounds are at increased risk for obesity and poor feeding and nutrition outcomes, but obesity prevention programs tailored specifically to the needs of these infants are lacking. the current study takes a community-engaged approach to development and delivery of an adaptively tailored obesity prevention program delivered via home visiting to target infant eating and feeding (healthy eating for my infant; hemi).

poor dietary habits and obesity-risk begin early in infancy. infants from underserved and minority backgrounds experience disparate rates of poor nutritional outcomes and subsequent health disparities related to obesity. each infant and their family experiences a unique set of risk factors and barriers to healthy eating. however, obesity prevention programs that are culturally and contextually relevant for underserved families and adapted based on the needs of individual families are lacking. the current study will develop an obesity prevention program, healthy eating for my infant (hemi), using a community-engaged approach involving community members in development and delivery of the program. hemi targets healthy infant feeding through six monthly sessions with infants 3-8 months old. the program will be delivered as a supplement to an already existing evidence-based home visiting program, every child succeeds (ecs), serving families with primarily low income and ethnic/racial minority backgrounds. development of an adaptive and effective obesity prevention program meeting the needs of underserved infants is critical for addressing health disparities in infant eating and obesity.

Eligibility criteria:
inclusion criteria: * infant enrolled in the every child succeeds (ecs) program * infant age is \< 2 months at study recruitment * infant born at \> 37 weeks gestation * infant is a singleton * maternal age is \> 18 years (in order to consent for child to participate) * mother is fluent in english or spanish exclusion criteria: * infant has a major medical condition that requires specialized feeding

Keywords: obesity prevention behavioral intervention health disparities trauma informed child nutrition responsive feeding infant
safety and efficacy the medigus srs endoscopic stapling system in gastroesophageal reflux disease (gerd)

Conditions: Gastroesophageal Reflux Disease (GERD)

Summary: the study is designed to test the safety and efficacy of the medigus srs endoscopic stapling system for the treatment of gerd. the system allows the operator to staple the stomach to the esophagus,in order to restore the gastroesophageal flap valve. the effect of the stapling is similar to a common operation for gerd (partial fundoplication) but is done through the mouth, and incision into the abdomen is not needed. the hypothesis of the study is that the treatment will be effective in improving gerd related quality of life by 50% or more in the majority of the subjects, and that the procedure will be as safe as surgery.


Eligibility criteria:
inclusion criteria: * history of gerd related symptoms for at least 2 years. * recent objective evidence of gerd, demonstrated by a 24h ph acid exposure test. * history of daily intake of proton pump inhibitors (ppis) for at least 6 months, with significant relief of symptoms (i.e., difference in gerd health related quality of life (gerd hrql) scores on and off ppi \> =6). * gerd-hrql ≥20 off of ppi's exclusion criteria: * hiatal hernia \> 3 cm or a paraesophageal hernia * barrett's esophagus or grade iv esophagitis * esophageal stricture, ring or web causing symptoms of dysphagia * grade i flap valve according hill's classification * history of co-morbidity

Keywords: gerd gastroesophageal reflux fundoplication endoluminal gastroesophageal flap valve
cord blood infusion for type 1 diabetes mellitus (t1dm)

Conditions: Type 1 Diabetes; Children

Summary: type 1 diabetes (t1d) is still associated with tremendous morbidity and premature mortality. patients require multiple daily insulin injections throughout their lives as well as close monitoring of their diet and blood sugar levels to prevent complications. unfortunately, there is presently no permanent cure for diabetes. whole pancreas or islet cell transplantation is available only to a very limited number of patients and necessitates potential lifelong immunosuppressive therapy. autologous stem cell transplants have been used successfully for all (acute lymphoblastic leukemia), aml (acute myeloblastic leukemia) and for the treatment of a variety of cancers including breast cancer and neuroblastomas, and more recently for the treatment of autoimmune disorders such as multiple sclerosis (ms), lupus-like disease, and rheumatic disorders. recently it was shown that bone marrow-derived stems cells transplanted into diabetic mice led to reduced hyperglycemia within 7 days after transplantation and was sustained until they were sacrificed at 35 days post-transplantation. the investigators' goal is to transfuse autologous umbilical cord blood into 23 children (germany 10 and 20 controls) with t1d in an attempt to regenerate pancreatic islet insulin producing beta cells and improve blood glucose control. as secondary goals, the investigators aim to track the migration of transfused cord blood stem and study the potential changes in metabolism/immune function leading to islet regeneration.


Eligibility criteria:
inclusion criteria: * must have a diagnosis of t1d and have stored umbilical cord blood (10 patients sought) at the cord bank vita 34. * tid diagnosis will be defined as having a clear history of polydipsia, polyphagia, polyuria, and weight loss consistent with a clinical diagnosis, diagnosis will mot be based solely upon the presence of autoantibodies. * cord blood meets all selection and testing criteria (see below). * normal screening values for cbc, renal function and electrolytes (bmp). * willing to comply with intensive diabetes management * not younger than 1 year of age exclusion criteria: * have complicating medical issues that would interfere with blood drawing or monitoring. * require chronic use of steroids or other immunosuppressive agents for other conditions. * cord blood with viability \< 50%. * positive infectious disease markers from mothers blood or cord at time of collection (see below for details). * any evidence of illness on planned infusion date (i.e. fever \>38.5 c, vomiting, diarrhea, wheezing, or crackles).
act for the home management in malagasy children

Conditions: Fever; Suspected Malaria

Summary: the purpose of this study is to assess the feasibility, the acceptability and the effectiveness of the use of the artesunate + amodiaquine fixed dose combination for the home management of presumed malaria in malagasy children by the community-based service providers.

primary objective to assess the feasibility, the acceptability and the effectiveness of the use of the artesunate + amodiaquine fixed dose combination for the home management of presumed malaria in malagasy children by the community-based service providers secondary objectives to assess the reliability of the use of the malaria rapid diagnostic tests (rdt) by the community-based service providers in the malagasy home management strategy to assess the frequency of short-term and long-term side effects of the artesunate + amodiaquine fixed dose combination used for the home management of presumed malaria in malagasy children by the community-based service providers to assess the real burden of the malaria in children under the age of five years in 2 different epidemiological strata of madagascar (central highlands and equatorial strata) type of study follow-up of a cohort of 1200 children under the age of five years during 1 year studied population all children under the age of five years (2 months to 5 years) having fever and consulting the community-based service provider, residing in the zone covered by the community-based service provider throughout the entire follow-up period investigators four community-based service providers, four field physicians and two supervisors number of district: 2 (moramanga and manakara) condition: fever intervention: artesunate + amodiaquine phase: phase iv

Eligibility criteria:
inclusion criteria: * all children under the age of five years (2 months to 5 years) having fever and consulting the community-based service provider, residing in the zone covered by the community-based service provider throughout the entire follow-up period, having signed an informed consent exclusion criteria: * children with no informed consent

Keywords: protozoan infections communicable diseases malaria infection malaria, falciparum malaria, vivax artesunate amodiaquine
ipc status as a surgical quality marker in rectal cancer surgery

Conditions: Rectal Cancer

Summary: risk of local recurrence after rectal surgery is nationally 8% after curative surgery to 5%. local recurrence rate after curative surgery varies between 3-7% in the variety of regions in the country. it is well known that the surgical technique total mesorectal excision (tme) has led to improved prognosis after rectal cancer surgery. tme surgery is difficult to perform and different factors affect the quality of tme preparations. injuries in mesorectal fascia has been reported in up to 20% of patients who underwent tme surgery and most surgeons agree that this may be important for recurrences. however, it is unclear to what extent a damaged mesorectal fascia can be related to a worsening of prognosis in patients with rectal cancer. adjuvant oncological treatment in form of chemotherapy after surgery, is offers patients with unfavorable tumors based on the pathological examination. patients with favorable tumors (less advanced) are not offered chemotherapy, even if the surgical technique was not optimal, ie. that there is damage in the mesorectal fascia, as evidence for this is lacking. the presence of intraperitoneal cancer cells (ipc) is related to histopathological tumor stage of colorectal cancer. incidence of ipc of intraperitoneal tumors (rectal cancer patients with tumors below the peritoneal reflection) is unclear. assessment of ipc status with cytology and immunohistochemistry is technically easy and could after tme surgery identify those patients who have an increased risk of tumor recurrence. in a positive ipc status, the patient would possibly benefit from either postoperative radiotherapy if the patient did not receive preoperative therapy, or postoperative oncological chemotherapy. tumour cells may be lysed in sterile water, and some surgeons rinse the abdominal cavity and the bowel distally to the tumour. neither rinsing the abdomen or rectum in colorectal cancer is routinely occurring and the clinical benefit has not been established. the value of rinsing the abdomen after tme-surgery could also be studied by ipc status. the study hypothesis is that the ipc status is dependent on the surgical quality of the specimen after tme-surgery in rectal cancer patients, and its presence leads to increased risk of local recurrence.


Eligibility criteria:
inclusion criteria: * rectal cancer patients that are going to be operated with bowel resection * control patients (10 patients) - patients with different conditions that are going to be operated. exclusion criteria: * none

Keywords: rectal carcinoma recurrence pathology cytology free cancer cells survival
additive effect of intravenous acetaminophen on postoperative pain control

Conditions: Postoperative Pain; Gynecologic Disease

Summary: this study aimed to evaluate the additive effect of acetaminophen on postoperative pain control in patients receiving nefopam and fentanyl-based patient-controlled analgesia. participants undergoing laparoscopic hysterectomy will be randomly assigned to treatment group or control group. after end of surgery, acetaminophen or normal saline (placebo) will be administered intravenously depending on the group assigned.


Eligibility criteria:
inclusion criteria: * patients undergoing total laparoscopic hysterectomy due to uterine myoma, cervical cancer, endometriosis, uterine prolapse exclusion criteria: * liver disease (aspartate transaminase or alanine transaminase \> 80 iu/l) * chronic kidney disease (gfr \< 30 ml/min/1.73m2) * history of drug allergy * chronic pain lasting more than 3 months * conversion to laparotomy * complex surgery (co-operation with colon surgeon or urologist) * limitation in expressing pain